A study of full treatment-free remission in patients with chronic myeloid leukemia

Trial details

Who runs it

Novartis Farma S.p.A.

Trial code

EU 2024-516122-66-00

Record updated

2025. július 9.

Original description

TFR1 stage: To determine the percentage of patients in full treatment-free remission 96 weeks after the start of consolidation. Full Treatment-Free Remission (FTFR) is defined as patients with Major Molecular Response (MMR) or better, including those who have totally discontinued treatment during the Treatment-Free Remission (TFR) phase and those who are treated with half the standard dosage. TFR2 stage: To estimate the percentage of patients in treatment-free remission 48 weeks after starting a second attempt at treatment-free remission (TFR2). Treatment-Free Remission (TFR) is defined as patients with Major Molecular Response (MMR) or better.Read full original descriptionShow less

A phase II, single-arm study of de-escalation and treatment-free remission in patients with chronic myeloid leukemia treated with nilotinib in first-line therapy followed by a second attempt after nilotinib and asciminib combination: DANTE study

TFR1 stage: To determine the percentage of patients in full treatment-free remission 96 weeks after the start of consolidation. Full Treatment-Free Remission (FTFR) is defined as patients with Major Molecular Response (MMR) or better, including those who have totally discontinued treatment during the Treatment-Free Remission (TFR) phase and those who are treated with half the standard dosage. TFR2 stage: To estimate the percentage of patients in treatment-free remission 48 weeks after starting a second attempt at treatment-free remission (TFR2). Treatment-Free Remission (TFR) is defined as patients with Major Molecular Response (MMR) or better.

Inclusion: TFR1 stage: Male and female patients 18 years or older; Male and female patients 18 years or older; Diagnosis of CP-CML according to the WHO and no previous history of progression to AP/BP CML; First-line treatment with nilotinib for at least 3 calendar years, followed by first TFR attempt; Failed first TFR attempt followed by at least 1 year of nilotinib retreatment before enrollment in TFR2 stage; MR4 or better (BCR-ABL ≤ 0.01% IS) assessed at screening; Patient must meet the following laboratory values at the reinduction screening visit: a. Absolute neutrophil count ≥1.0 x 109/L b. Platelets ≥75 x 109/L c. Hemoglobin (Hgb) ≥ 9 g/dL d. Serum creatinine < 1.5 mg/dL e. Total bilirubin ≤ 2 x ULN except for patients with Gilbert’s syndrome who may only be included if total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN f. AST ≤ 3.0 x ULN g. ALT ≤ 3.0 x ULN h. Alkaline phosphatase ≤ 2.5 x ULN i. Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN - ≤ 1.5 x ULN, value must be considered not clinically significant and not associated with risk factors for acute pancreatitis j. Serum levels of potassium, magnesium, total calcium within the normal limits. Correction of electrolytes levels with supplements to fulfil enrolment criteria is allowed; ECOG performance status 0-2; Study subjects must be able to comply with study procedures and follow-up examinations; Diagnosis of CML-CP according to the World Health Organization; Patients with CML-CP under first-line treatment with nilotinib at the approved daily dose of 300 mg BID mg for at least 3 calendar years. Note: At study entry, an ongoing treatment at a dose ≥400 mg per day is allowed; Sustained DMR defined as ≥ MR 4.0 (BCR-ABL level ≤0.01% IS) in all of the last 4 BCR-ABL RQ-PCR assessments with a minimum interval between each assessment of 3 months and a maximum interval of 6 months; Patient must meet the following laboratory values at the screening visit: • Absolute Neutrophil Count ≥1.0 x 109/L • Platelets ≥75 x 109/L • Hemoglobin (Hgb) ≥ 9 g/dL • Serum creatinine < 1.5 mg/dL • Aspartate transaminase (AST) ≤ 3.0 x Upper Limit of Normal (ULN) • Alanine transaminase (ALT) ≤ 3.0 x ULN • Serum lipase ≤ 2 x ULN; Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-2; Study subjects must be able to comply with study procedures and follow-up examinations; Signed informed consent to the TFR1 stage from the patient or from his/her legal representative; TFR2 stage: Signed informed consent to the TFR2 stage from the patient or from his/her legal representative.

Exclusion: Patients who have not recovered from prior surgery; Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks of Day 1; Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry; Patients actively receiving therapy with herbal medicines that are strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry. These herbal medicines may include Echinacea, (including E. purpurea, E. angustifolia and E. pallida), Piperine, Artemisinin, St. John's Wort, and Ginkgo; Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for at least 14 days after stopping medication. There is a limited amount of data on pregnancies in patients while attempting treatment-free remission (TFR). If pregnancy is planned during the TFR phase, the patient must be informed of a potential need to re-initiate treatment with nilotinib during pregnancy; Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol; History of acute pancreatitis within 1 year prior to study entry or past medical history of chronic pancreatitis; History of other active malignancy within 5 years prior to study entry except for previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ treated curatively; Patients who have not recovered from prior surgery; Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks; Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry; Patients actively receiving therapy with herbal medicines that are strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry. These herbal medicines may include Echinacea, (including E. purpurea, E. angustifolia and E. pallida), Piperine, Artemisinin, St. John's Wort, and Ginkgo; Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for at least 14 days after stopping medication. There is a limited amount of data on pregnancies in patients while attempting treatment-free remission (TFR). If pregnancy is planned during the TFR phase, the patient must be informed of a potential need to re-initiate treatment with nilotinib during pregnancy; Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol; History of acute pancreatitis within 1 year prior to study entry or past medical history of chronic pancreatitis; History of other active malignancy within 5 years prior to study entry except for previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ treated curatively; Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery); Known presence of a significant congenital or acquired bleeding disorder unrelated to cancer; Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery); Known presence of a significant congenital or acquired bleeding disorder unrelated to cancer; Known impaired cardiac function including any one of the following: • Inability to determine QT interval on ECG • Complete left bundle branch block • Long QT syndrome or a known family history of long QT syndrome • History of or presence of clinically significant ventricular or atrial tachyarrhythmias • Clinically significant resting bradycardia • QTcF > 450 msec (male) or > 460 msec (female) • History or clinical signs of myocardial infarction within 1 year prior to study entry • History of unstable angina within 1 year prior to study entry • Other clinically significant heart disease (e.g. uncontrolled congestive heart failure or uncontrolled hypertension); Known impaired cardiac function including any one of the following: • Inability to determine QT interval on ECG • Complete left bundle branch block • Long QT syndrome or a known family history of long QT syndrome • History of or presence of clinically significant ventricular or atrial tachyarrhythmias • Clinically significant resting bradycardia • QTcF > 480 msec • History or clinical signs of myocardial infarction within 1 year prior to study entry • History of unstable angina within 1 year prior to study entry • Other clinically significant heart disease (e.g. uncontrolled congestive heart failure or uncontrolled hypertension); TFR1 stage: Patients with known atypical transcript; Pregnant or nursing (lactating) women; TFR2 stage: Patients with known atypical transcript; CML treatment resistant mutation(s) (T315I, E255K/V, Y253H, F359C/V) detected if testing was done in the past (there is no requirement to perform mutation testing at study entry if it was not done in the past); Dose reductions/interruptions due to neutropenia or thrombocytopenia in the past 6 months; CML treatment resistant mutation(s) (T315I, E255K/V, Y253H, F359C/V) detected if testing was done in the past (there is no requirement to perform mutation testing at study entry if it was not done in the past); Dose reductions/interruptions due to neutropenia or thrombocytopenia in the past 6 months; Pregnant or nursing (lactating) women; Patient ever attempted to permanently discontinue nilotinib treatment.

EU CTIS 2024-516122-66-00